Key Opinion Leaders Will Provide Updated
Results on Efficacy, Safety and Delivery of MDNA55
TORONTO and HOUSTON, Nov. 14,
2019 /PRNewswire/ - Medicenna Therapeutics Corp.
("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a
clinical stage immuno-oncology company, today announced that key
opinion leaders, Dr. Sampson and Dr. Butowski, will present updated
results from the Phase 2b clinical
trial of MDNA55 for the treatment of recurrent glioblastoma
("rGBM") at the 24th Annual Meeting of the Society of
Neuro-Oncology ("SNO") and 3rd Joint Conference of SNO and Society
for CNS Interstitial Delivery of Therapeutics ("SNO-SCIDOT") to be
held from November 20 to 24 at the JW
Marriott Desert Ridge Resort in Phoenix,
Arizona.
The oral presentations will provide an update on efficacy,
safety and data from the MDNA55 Phase 2b clinical trial in patients with rGBM, the most
common and deadly form of brain cancer.
Details of the presentations are as follows:
Presenter: Dr. Nicholas
Butowski, MD – Professor of Neurological Surgery and
Director of Translational Research in Neuro-Oncology at
The Helen Diller Family Comprehensive Cancer
Center, University of California San Francisco
Title: Convection-Enhanced Delivery (CED) of MDNA55 in
Adults with Recurrent Glioblastoma
Date/Time: Wednesday, November 20, 2019 at 3:10 PM MT
Room: Grand Saguaro East
Presenter: Dr. John
Sampson, MD, PhD, MHSc, MBA - Robert and Gloria Wilkins
Distinguished Professor and Chair of Neurosurgery, Department of
Neurosurgery, Duke University School of
Medicine
Title: Combating Recurrent Glioblastoma with MDNA55, an
Interleukin-4 Receptor Targeted Immunotherapy, Through MRI-Guided
Convective Delivery
Date/Time: Sunday, November 24, 2019 at 9:45 AM MT
Room: Grand Canyon 1 – 6
About Medicenna Therapeutics Corp.
Medicenna is a
clinical stage immunotherapy company focused on oncology and the
development and commercialization of novel, highly selective
versions of IL-2, IL-4 and IL-13 Superkines and first in class
Empowered Cytokines™ (ECs) for the treatment of a broad range of
cancers. Supported by a US$14.1M
non-dilutive grant from CPRIT (Cancer Prevention and Research
Institute of Texas), Medicenna's
lead IL4-EC, MDNA55, has completed enrolling patients in a Phase
2b clinical trial for rGBM, the most
common and uniformly fatal form of brain cancer, at top-ranked
brain cancer centres in the US. MDNA55 has been studied in five
clinical trials involving 132 patients, including 112 adults with
rGBM. MDNA55 has demonstrated compelling efficacy and has obtained
Fast-Track and Orphan Drug status from the FDA and FDA/EMA
respectively. For more information, please visit
www.medicenna.com.
View original
content:http://www.prnewswire.com/news-releases/medicenna-announces-presentations-on-mdna55-recurrent-glioblastoma-clinical-trial-at-the-annual-meeting-of-the-society-of-neuro-oncology-300958326.html
SOURCE Medicenna Therapeutics Corp.